ROP

Feinstein researchers highlight breakthroughs in brain tumor treatments

Rose Weldon
From last year's Brain Tumor Biotech Summit (from left to right), Dr. Steven Kalkanis; Dr. John Boockvar; Dr. William Curry; and Marc Symons. (Photo courtesy of Northwell Health)

Physicians from the Feinstein Institutes for Medical Research in Manhasset and the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell in Garden City, have co-authored a comprehensive update on biotechnology breakthroughs in brain tumor research.

The paper, entitled “Update on Glioma Biotechnology” and cowritten in collaboration with the department of neurosurgery at Lenox Hill Hospital in Manhattan, is a culmination of all three institutes’ neuro-oncology research and emerging therapies, much of which was presented at the 2019 Brain Tumor Biotechnology Summit at Lenox Hill, according to paper coauthor Dr. John Boockvar, who serves as vice chair of neurosurgery at Lenox Hill Hospital and co-director of the Feinstein Institutes’ Brain Tumor Biotech Center.

“The goal of the Brain Tumor Biotech Summit is to provide a forum that encourages collaboration between cancer specialists, biotechnology and pharmaceutical industry leaders, and the investment community in order to promote innovation and advance emerging therapies for brain tumors,” Boockvar said. “With our published work, my colleagues and I have provided an update regarding emerging therapies for brain tumors, including receptor targeting, methods for improved blood brain barrier disruption with intra-arterial drug delivery and other innovative intraoperative techniques and technologies.”

The report discusses the progress that has been made in brain tumor biotechnology and highlights innovative advances in the treatment of malignant brain tumors, with new information regarding various therapies used, including updated results, along with detailed information about new and ongoing clinical trials.

“Dr. Boockvar established an interdisciplinary effort to ignite progress in brain tumor research,” said Dr. Kevin J. Tracey, president and CEO of the Feinstein Institutes. “This review highlights the potential for collaborative strategies, offering hope new therapies may be on the horizon for patients with glioblastoma multiforme.”

“Update on Glioma Biotechnology” was co-authored by Marc Symons of the Feinstein Institutes; Madeline Abrams and Dr. Christopher G. Filippi of the Zucker School of Medicine;  and Mona Li, Sherese Fralin, Tamika Wong, Noah Reichman, Dr. Nitesh V. Patel, Dr. Randy D’Amico, Dr. David Langer, Dr. Deepak Khatri and the aforementioned Boockvar of Lenox Hill Hospital.

About the author

Rose Weldon

Share this Article